Sirolimus (Rapamune® / Rapamycin) – Advanced Support for Feline Hypertrophic Cardiomyopathy (HCM)

Sirolimus (Rapamune® / Rapamycin) is an conditional FDA-approved mTOR inhibitor widely studied in veterinary medicine. In recent veterinary cardiology research, Sirolimus has shown promising potential in the management of hypertrophic cardiomyopathy (HCM) in cats, particularly for slowing disease progression and improving cardiac function under veterinary supervision.

Sirolimus works by selectively inhibiting the mammalian target of Rapamycin (mTOR) pathway, a key regulator of:

• Cellular growth and proliferation

• Pathological myocardial hypertrophy

• Cardiac remodeling and fibrosis

In feline HCM, dysregulation of the mTOR pathway is believed to contribute to abnormal thickening of the ventricular walls. Sirolimus may help slow or modulate this pathological process, rather than simply managing symptoms.